Corporate Presentation
November 2023
PeptiDream Inc.
(TSE : 4587)
PeptiDream - Investment Highlights
Global Leader in the Discovery and Development of Macrocyclic Peptide Therapeutics
Industry Leading
Peptide Discovery
Platform
PeptiDream's proprietary Peptide Discovery Platform System (PDPS) technology
- Unparalleled peptide library generation (trillions) and hit finding platform
- Unrivaled # of building blocks
- Continuous evolution of the technology, translating learnings from advancing programs back into the platform improvements
- World-classchemistry, biology, bioinformatics, structural biology, modeling, profiling and ADME teams to turn hit peptide candidates into development candidates
Strong IP portfolio
Foundational in
Leading and Expanding
the Field
PeptiDream at the center of a large and diverse network of discovery and development partnerships
- Collaborations with large, mid, and small sized pharma companies all over the world creating the ecosystem
- Licensing of the PDPS discovery platform to global and Japan pharma partners solidifies the network around a common platform.
- Further grow the network and modality through strategic partnerships
- Develop products in house and license to network partners
Diverse Big Pharma-
Sized Pipeline
PeptiDream has a large diverse pipeline of programs spanning peptide modality, disease areas and development partners
- Over 120+ discovery and development programs
- Spans variety of peptide modalities, from peptide therapeutics to peptide-drug conjugates (PDCs) to multi- functional peptide conjugates (MPCs)
- Across broad range of therapeutic areas and discovery and development partners
Markets 24 radiodiagnostic and 8 radiotherapeutic products in Japan through PDRadiopharma
Business Model
Driving Profitability
and Growth
PeptiDream's unique multifaceted business model has allowed company to be profitable since 2011
- Year over year growth in revenue and profits from three complementary and synergistic business strategies
- Grow the business and the pipeline through partnerships and cash flow, not through capital raises
- Phenomenal growth potential as the pipeline matures
Japan radiopharmaceutical and radiodiagnostic business provides stable, positive cash flow
2
PeptiDream - Historical Snapshot
From University Startup to Growing Japan-Based Drug Discovery Powerhouse
PeptiDream Inc.
Selected as a constituent of The JPX Prime 150 Index
2023
PDRadiopharma Inc.
PDRadiopharma Chiba Plant | Acquired PDRadiopharma Inc. |
(Radiopharmaceutical business) | |
Changed to the Prime Market | |
of the TSE |
Relocated corporate headquarters
2022
JPY 30.0 B1)/
704 employees2)
JPY 26.8 B/
PeptiDream headquarters (Kawasaki)
to Kawasaki
680 employees
PeptiDream Founded
(Spinout from the University of Tokyo)
2006
Revenue/
Total employees
Changed to the first section of the TSE
2015 | |
JPY 2.4B / | |
JPY 0.6B / | 50 employees |
32 employees |
2017
JPY 4.8B/
68 employees
Note: Financial numbers prior to FY2021 are based on JGAAP, IFRS is applied after FY2022.
1) Consolidated revenue forecast for FY2023 2) PeptiDream Inc.: 208 employees, PDRadiopharma Inc.: 496 employees (as of June 2023)
3
PeptiDream's Equity Holdings
Key progress on programs with the partners
Computational Drug Discovery (2017-)
- Partnering discussions in progress for KIT inhibitor program
Radiopharmaceutical
Development,
Manufacturing and
Sales (2022-)
- Indication expansion of AMYViD approved for the use of MCI
- In-licensingdiscussions to accelerate short-term pipeline growth
Note: (Year) represents the year that PeptiDream invested in the company.
<5%
2%
<15%
39.5%
39.4%
100%
Strategic Partner in Radiopharmaceuticals (2020-)
- Announced the 2nd development candidate from PeptiDream collaboration
- IND-enablingstudies and imaging studies in humans on-going, with the plan to file INDs in H1 2024
Peptide CDMO Business (2017-)
- Expanding the peptide and oligonucleotide API manufacturing business
- Progress in development of new platform technologies
Growth Factor Business (2020-)
- 7 products currently in the market
- Targeting market opportunities in lab-grown meat in addition to regenerative medicine and cell therapy
- Partnering discussions for therapeutic use
COVID-19 Therapeutics (2020-)
- Confirmed favorable safety profile in humans (clinical research in Japan)
- Anticipate US phase 1 trial to start in Q1 2024, with financial support from AMED
4
Macrocyclic Peptides as an Expanding Drug Class
Several Approved Macrocyclic Peptide Drugs With Over $1B in Annual Sales
Long History of Macrocyclic Peptides As Drugs Macrocyclic Peptides Have Positive Features of Both Small & Large Molecules
Molecular weight
Large | ||||||||||
Small | ||||||||||
0.6kD | 2.5kD | 150kD~ | ||||||||
Small molecules | Macrocyclic peptides | Large molecules | ||||||||
• | Good at recognizing | • High affinity and specificity | • | High affinity and | |
binding pockets but | • | Good at inhibiting PPIs | specificity | ||
not PPIs or shallow | • Good at recognizing shallow | • | Good at inhibiting PPIs | ||
surfaces | interacting surfaces and | • | Good at recognizing | ||
• | Orally bioavailable | binding pockets | shallow interacting | ||
• | Membrane permeable | • | Oral bioavailability possible | surfaces of proteins | |
• | Near limitless targets | • | Near limitless targets | • Not oral - limited targets | |
• | However difficult and | • Relative ease and speed in | • Relative ease and speed | ||
time consuming to find | finding a suitable hit | in finding a suitable hit |
Most approved macrocyclic drugs arose from natural products, limiting discovery!
Note: 1) Approved by CDER (Center for Drug Evaluation and Research) as new molecular entities. | 5 |
Source: FDA, Chemistry & Engineering News, Company websites. |
PDPS is a Powerful Peptide Discovery Platform
Unparalleled Macrocyclic Peptide Library Generation and Hit Finding Technology
Amino Acid (AA) Building Blocks
PeptiDream's 3000+ AAs:
• | Canonical AAs | |
• | Non-canonical AAs | |
‒ L-AAs w/ novel side chains | ||
‒ | N-alkyl AAs | |
‒ | D-AAs |
Randomized DNA library
10 positions with 20
building blocks
2010 =
10,240,000,000,000 different peptides in a library
Trillions of peptides
in each library
Cyclic peptide
Coding sequence
- Robust, cell-free synthesis derived by nature's way of making peptides
- Each peptide "barcoded" via its mRNA/cDNA tag
‒ | β-AAs |
‒ | Peptoid AAs |
etc.
Continuously evolving
platform
- Continuous expansion of AA building blocks that libraries can be made with and optimized from ( grew from 200 to >3,000 )
- Automation of the platform (high throughput)
- Growing in-silico methods, computer simulation and modeling to predict optimal features
- Protected by a broad patent portfolio
Amplify recovered
sequences and repeat
Amplify candidate peptides over iterative rounds of selection
Target protein
Magnetic bead
Automated PDPS
Workstation
Peptide binder
High rate of hit finding success
-
Discover high affinity and highly selective macrocyclic peptide binders to almost any target quickly and efficiently
Yields unique hit candidates unlike any other technology
Technology can be used to optimize and fine-tune the drug-like properties
6
The Expanding Applications of Macrocyclic Peptides
Turning PDPS Identified Seeds Into a Growing Array of Peptide Therapeutics
PDPS Identified
Macrocyclic
Peptide Seeds
Peptide Drugs
Small Molecule Drugs
Peptide-RI
PDCs Peptide-Oligo
Peptide-Cytotoxic
Bifunctional
MPCs
Trifunctional
Key Advantages
- Affinity and selectivity comparable to antibodies
- Unique epitopes and MOAs
- Differentiating PK & ADME characteristics
- Oral administration & other routes possible
- Enable small molecule discovery
- Peptide ideal at targeting and payload delivery
- More amenable to a greater array of payloads compared to other modalities.
- Simple robust conjugation chemistry
- Tunable PK/ Differentiating route of elimination
- RI-PDC: Ideal fit with radioisotope payloads
- Oligo-PDC: Enable delivery of oligonucleotide/siRNA drugs to specific tissues/cells
- Cytotoxic-PDC: unique beneficial attributes
- Extremely powerful and modular
- Design and generate multi-functional peptide drugs by conjugating/linking several peptides with different MOAs together
- Various configurations, such as bifunctional, trifunctional, and more
7
Expansion of R&D Capabilities
Unlocking Greater Value and Increasing Control
PeptiDream's role in collaborations has increased over time
R&D Capabilities (2010)
Hit ID | Lead | Lead | Preclinical | Phase 1 |
Generation | Optimization | Studies | ||
R&D Capabilities (2023)
Hit ID | Lead | Lead | Preclinical | Phase 1 |
Generation | Optimization | Studies | ||
Increasing research capabilities allows for:
- Greater role in partnerships
- More control over program progress
- Larger deal financials
- Ability to take internal programs further before partnering/ out-licensing
Radiopharmaceutical Operations | |||||||||
# of | (Sales, Commercial, Distribution, | ||||||||
Increasing value of | |||||||||
Manufacturing, R&D) | |||||||||
employees | all programs | ||||||||
800 | |||||||||
PDPS automation 680 | |||||||||
Translational Research | |||||||||
600 | |||||||||
ADME/PK | PDRadiopharma | ||||||||
Structural Biology | |||||||||
400 | |||||||||
Discovery Biology | |||||||||
Medicinal Chemistry | |||||||||
Modeling/Informatics | |||||||||
200 | Peptide Chemistry | ||||||||
Amino Acid Expansion |
PDPS | PeptiDream |
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Company | Relocation to | Acquisition of | ||
founded | Kawasaki | PDRadiopharma |
8
Unique Multifaceted Business Model
Business Model Spread Across 4 Strategies
Drug Discovery and Development Business Segment
1 | Collaboration Drug |
Discovery and Development |
2 PDPS Technology Licensing
Strategic Alliance/
3 In-House Program
Radiopharmaceuticals Business Segment
100%
Revenue Source
Short-termMid-termLong-term
Upfront
Development
Research fundingRoyalties milestones
Preclinical milestones
Licensing and | Development | Royalties |
maintenance fees | milestones | |
Out-licensing fee,
developmentRoyalties milestones
R&D, Manufacturing and Sales of
4 Radiopharmaceuticals/Diagnostics
Product Sales | Product Sales | Product Sales |
(Existing | (In-licensed | (PeptiDream |
products) | products) | products) |
9
1 Collaboration Drug Discovery and Development
Combining PeptiDream's Expertise With Big Pharma's Drug Development Know-How and Capabilities
- Lead & Expand: Leadership position in the space - drive expansion of macrocyclic peptide ecosystem
- More Programs: Allows PeptiDream to work on a larger number of programs with less staff/resources than otherwise possible
- Build Expertise: Continuously build in-house expertise by working with and learning from big pharma
- Diversify Risk: Diversify business risk with a broad portfolio of programs and partners (success not tied to any one program or partner)
5-Year Snapshot | |||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
Peptide Therapeutics
Multiple undisclosed targets
PDC | PDC | PDC | ||
PDCs for brain/CNS | Radiological diagnostics and | |||
delivery | novel applications | PDCs for CNS diseases |
Peptide Therapeutics Peptide Therapeutics
cMET agonist program | Multiple undisclosed targets |
Peptide Therapeutics | PDC | |
Ophthalmic disease targets | PDCs with RI payloads |
Peptide Therapeutics | PDC | PDC | PDC | |||
Peptide-siRNA delivery to | PDCs with cytotoxic | |||||
COVID-19 therapies | extrahepatic tissues | payloads | Targeted protein degraders |
Note: Merck & Co., Inc., Rahway, NJ, USA.
PDC | PDC | PDC | ||
PDCs for neuromuscular | PDCs targeting specific cells | |||
diseases | and tissues | Peptide-RI drug conjugates |
10
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
PeptiDream Inc. published this content on 01 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2023 09:13:44 UTC.